InnoPharmax Inc.
InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and… Read more
InnoPharmax Inc. (4172) - Total Assets
Latest total assets as of June 2025: NT$595.85 Million TWD
Based on the latest financial reports, InnoPharmax Inc. (4172) holds total assets worth NT$595.85 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
InnoPharmax Inc. - Total Assets Trend (2019–2024)
This chart illustrates how InnoPharmax Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
InnoPharmax Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
InnoPharmax Inc.'s total assets of NT$595.85 Million consist of 50.6% current assets and 49.4% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 26.3% |
| Accounts Receivable | NT$4.78 Million | 0.8% |
| Inventory | NT$18.34 Million | 2.9% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$6.22 Million | 1.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how InnoPharmax Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: InnoPharmax Inc.'s current assets represent 50.6% of total assets in 2024, an increase from 0.8% in 2019.
- Cash Position: Cash and equivalents constituted 26.3% of total assets in 2024, up from 21.1% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 2.9% of total assets.
InnoPharmax Inc. Competitors by Total Assets
Key competitors of InnoPharmax Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM
|
USA | $41.43 Million |
|
High Sierra Technologies Inc
PINK:HSTI
|
USA | $10.70K |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
InnoPharmax Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - InnoPharmax Inc. generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - InnoPharmax Inc. is currently not profitable relative to its asset base.
InnoPharmax Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.80 | 3.81 | 3.49 |
| Quick Ratio | 6.34 | 3.39 | 2.73 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$248.75 Million | NT$ 116.00 Million | NT$ 97.61 Million |
InnoPharmax Inc. - Advanced Valuation Insights
This section examines the relationship between InnoPharmax Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.60 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 20.8% |
| Total Assets | NT$633.06 Million |
| Market Capitalization | $41.28 Million USD |
Valuation Analysis
Below Book Valuation: The market values InnoPharmax Inc.'s assets below their book value (0.07 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: InnoPharmax Inc.'s assets grew by 20.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for InnoPharmax Inc. (2019–2024)
The table below shows the annual total assets of InnoPharmax Inc. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$633.06 Million | +20.77% |
| 2023-12-31 | NT$524.20 Million | +7.13% |
| 2022-12-31 | NT$489.31 Million | -12.02% |
| 2021-12-31 | NT$556.16 Million | -18.23% |
| 2020-12-31 | NT$680.18 Million | +13.99% |
| 2019-12-31 | NT$596.71 Million | -- |